Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14880612 | 0.88 | KDM1A (0.46) | KDM1AMAOBMAOA | |
| SCHEMBL14880582 | 0.82 | TSHR (0.56) | KDM1ASMN1; SMN2MAOBKMT2AMAOA | |
| SCHEMBL14880821 | 0.79 | KDM1A (0.47) | KDM1AMAOBMAOA | |
| SCHEMBL14880977 | 0.77 | KDM1A (0.48) | KDM1AMAOBMAOA | |
| SCHEMBL14880470 | 0.77 | CYP19A1 (0.49) | KDM1AALDH1A1GAAMAOB | |
| SCHEMBL16017647 | 0.75 | KMT2A (0.62) | ALDH1A1GAAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL13684325 | 0.72 | BRD4 (0.56) | ALDH1A1GAAMAPTMEN1KMT2A | |
| SCHEMBL14880547 | 0.70 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL16394487 | 0.70 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL21841002 | 0.70 | KDM1A (1.00) | KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107266345-B | (hetero) arylcyclopropylamine compounds as LSD1 inhibitors | 奥瑞泽恩基因组学股份有限公司 | 2021-08-17 | — | — | CN | claimed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | claimed |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2017-01-12 | — | — | US | claimed |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-01-22 | — | — | US | claimed |
| CN-104203914-A | (hetero) arylcyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS SA | 2014-12-10 | — | — | CN | claimed |
| EP-2768805-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2014-08-27 | — | — | EP | claimed |
| WO-2013057320-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | claimed |
| CN-107266345-B | (hetero) arylcyclopropylamine compounds as LSD1 inhibitors | 奥瑞泽恩基因组学股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2018-12-13 | — | — | US | disclosed |
| US-9944601-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2018-04-17 | — | — | US | disclosed |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2017-01-12 | — | — | US | disclosed |
| US-9487512-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-11-08 | — | — | US | disclosed |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-01-22 | — | — | US | disclosed |
| CN-104203914-A | (hetero) arylcyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS SA | 2014-12-10 | — | — | CN | disclosed |
| EP-2768805-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013057320-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885ALDH1A1 562/4885GAA 1762/4885 |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885ALDH1A1 562/4885GAA 1762/4885 |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885ALDH1A1 562/4885GAA 1762/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | KDM1A 2/4885ALDH1A1 562/4885GAA 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.